Our western blot analysis results therefore confirmed our hypothesis of targeting various cellular signaling pathways including PI3K/Akt, RAS/MAPK and BRD4 degradation to finally target c-Myc oncogene by simultaneous delivery of PL-NANO and AL-NANO in BRAFi-resistant melanoma. Here, BRD4 is linked to melanoma.